Dose released and absolute bioavailability of nicotine from a nicotine vapor inhaler

被引:33
作者
Molander, L
Lunell, E
Andersson, SB
Kuylenstierna, F
机构
[1] PHARMACIA,DEPT CLIN PHARMACOL,S-22220 LUND,SWEDEN
[2] UNIV HOSP,DEPT CLIN PHARMACOL,S-22220 LUND,SWEDEN
[3] PHARMACIA,DEPT PHARMACEUT RES & DEV,HELSINGBORG,SWEDEN
关键词
D O I
10.1016/S0009-9236(96)90107-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In an open, randomized, three-way crossover study, 14 healthy smokers used one type of nicotine vapor inhaler intensely for 20 minutes every hour for 11 hours (12 administrations). Two different inhalation techniques were applied, shallow frequent sucking (buccal mode) and deep inhalations (pulmonary mode), liquid extraction of the plasma sample, Nicotine was detected by means of a nitrogen-sensitive detector, giving high selectivity and sensitivity. The mean (+/-SD) nicotine dose released from each nicotine vapor inhaler unit was estimated at 4.00 +/- 0.60 mg (buccal mode) and 3.87 +/- 0.75 mg (pulmonary mode), inhaled with approximately 15 L of air, Mean (+/-SD) peak plasma level of the last dosing interval was 32.0 +/- 8.7 ng/ml and 34.2 +/- 8.9 ng/ml for the buccal and the pulmonary technique, respectively, achieved after 0.33 and 0.50 (median) hour, respectively. The mean (95% confidence interval [CI]) absolute bioavailability of nicotine was 51 (95% CI, 40 to 65) and 56 (95% CI, 47 to 67) when the buccal and pulmonary techniques mere used, respectively, A significant correlation was found between systemically available dose and average steady state nicotine plasma concentration, Based on the achievement of similar nicotine plasma levels, it may be concluded that the two modes of inhalation appear to be clinically equivalent.
引用
收藏
页码:394 / 400
页数:7
相关论文
共 11 条
[1]   REGIONAL DEPOSITION OF INHALED C-11 NICOTINE VAPOR IN THE HUMAN AIRWAY AS VISUALIZED BY POSITRON EMISSION TOMOGRAPHY [J].
BERGSTROM, M ;
NORDBERG, A ;
LUNELL, E ;
ANTONI, G ;
LANGSTROM, B .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1995, 57 (03) :309-317
[2]  
LUNELL E, 1995, EUR J CLIN PHARMACOL, V48, P235
[3]  
MCNABB ME, 1984, CAN MED ASSOC J, V131, P589
[4]  
NEMETHCOSLETT R, 1987, 95 ANN CONV AM PSYCH
[5]  
NEWMAN SP, 1981, THORAX, V36, P52, DOI 10.1136/thx.36.1.52
[6]  
ROSE JE, 1988, NICOTINE REPLACEMENT, P95
[7]   NICOTINE REPLACEMENT IN SMOKING CESSATION - ABSORPTION OF NICOTINE VAPOR FROM SMOKE-FREE CIGARETTES [J].
RUSSELL, MAH ;
JARVIS, MJ ;
SUTHERLAND, G ;
FEYERABEND, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1987, 257 (23) :3262-3265
[8]   NICOTINE THERAPY IN SMOKING CESSATION - PHARMACOKINETIC CONSIDERATIONS [J].
SCHNEIDER, NG .
CLINICAL PHARMACOKINETICS, 1992, 23 (03) :169-172
[9]   THE DELIVERY AND UPTAKE OF NICOTINE FROM AN AEROSOL ROD [J].
SEPKOVIC, DW ;
COLOSIMO, SG ;
AXELRAD, CM ;
ADAMS, JD ;
HALEY, NJ .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1986, 76 (11) :1343-1344
[10]   HOW EFFECTIVE IS NICOTINE REPLACEMENT THERAPY IN HELPING PEOPLE TO STOP SMOKING [J].
TANG, JL ;
LAW, M ;
WALD, N .
BRITISH MEDICAL JOURNAL, 1994, 308 (6920) :21-26